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Abstract
We report herein that trefoil factor 3 (TFF3) is oncogenic and mediates anti–estrogen resistance in human mammary carcinoma.
Forced expression of TFF3 inmammary carcinoma cells increased cell proliferation and survival, enhanced anchorage-independent
growth, and promoted migration and invasion. Moreover, forced expression of TFF3 increased tumor size in xenograft models.
Conversely, depletion of endogenous TFF3 with small interfering RNA (siRNA) decreased the oncogenicity and invasiveness of
mammary carcinoma cells. Neutralization of secreted TFF3 by antibody promoted apoptosis, decreased cell growth in vitro, and
arrested mammary carcinoma xenograft growth. TFF3 expression was significantly correlated to decreased survival of estrogen
receptor (ER)–positive breast cancer patients treated with tamoxifen. Forced expression of TFF3 in mammary carcinoma cells in-
creased ER transcriptional activity, promoted estrogen-independent growth, and produced resistance to tamoxifen and fulvestrant
in vitro and to tamoxifen in xenograft models. siRNA-mediated depletion or antibody inhibition of TFF3 significantly enhanced
the efficacy of antiestrogens. Increased TFF3 expression was observed in tamoxifen-resistant (TAMR) cells and antibody inhibi-
tion of TFF3 in TAMR cells improved tamoxifen sensitivity. Functional antagonism of TFF3 therefore warrants consideration as a
novel therapeutic strategy for mammary carcinoma.
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Introduction
Trefoil factor 3 (TFF3), previously designated as intestinal trefoil factor,
belongs to the trefoil factor (TFF) family, which includes two other
members, namely TFF1 and TFF2 [1]. All three TFF proteins are ex-
pressed in the epithelial cells that line mucous membranes, usually from
mucin-secreting goblet cells. TFF1 is predominantly expressed in the
stomach and colon, TFF2 expression is mainly localized in the stom-
ach, whereas TFF3 expression is observed predominantly in the intes-
tine [2,3]. TFF3 and other TFF members are classically involved in the
protection of gastrointestinal tract against mucosal injury and subse-
quent repair [4]. TFF peptides act as motogen to facilitate cell migra-
tion and also inhibit apoptosis and prevent anoikis in the process of cell
migration [4,5].
In addition to the protective and restorative effects of TFF3 in the
gastrointestinal tract, compelling evidence has emerged from experi-
mental and clinical studies to indicate a pivotal role of TFF3 in neoplas-
tic diseases. TFF3 is overexpressed in a variety of human malignancies
including mammary [6], gastric [7,8], prostate [9], hepatocellular [10],
and endometrial [11] carcinomas, and it has demonstrated prosurvival,
proinvasive, and proangiogenic activities in cells derived from several
common human solid tumors [12–17].
TFF3 messenger RNA (mRNA) is focally expressed in duct luminal
cells of normal mammary gland and exhibits increased expression in
both in situ and invasive carcinomas [6]. Although the role of TFF3
in mammary carcinoma remains undefined, the prognostic or predic-
tive value of TFF3 expression in mammary carcinoma has been indi-
cated by several clinical studies. TFF3 mRNA expression has been
demonstrated to predict micrometastatic breast cancer [18] and is
strongly correlated with breast cancer metastatic to bone [19]. Serial
analysis of gene expression has included TFF3 in a signature of genes
that are expressed in mammary carcinoma but absent from blood and
bone marrow [20]. TFF3 has been identified as one of a panel of four
genes that accurately detected minimal residual disease in blood and
predict survival in breast cancer patients with metastatic disease [21].
In addition, TFF3 along with TFF1 has been used as a marker for the
detection of disseminated breast cancer cells [22]. Notably, in malig-
nancies of the human mammary gland, TFF3 and TFF1 are observed
to coexpress [6,23] and coregulate each other in a positive feedback
loop [24].Moreover, bothTFF1 andTFF3 are estrogen-regulated genes
[23]. TFF1 has recently been demonstrated to be oncogenic in human
mammary carcinoma cells [25].We therefore speculated that TFF3may
possess similar functions as TFF1 and contribute to the malignant be-
havior of mammary carcinoma cells. This hypothesis is also supported
by our previous study, which demonstrated that TFF3 partially medi-
ated oncogenic transformation stimulated by autocrine human growth
hormone [26].
The purpose of this study was to systematically delineate the func-
tional role of TFF3 in mammary carcinoma and investigate the effects
of TFF3 on the cellular response to estrogen and antiestrogenic agents.
We report herein that TFF3 is oncogenic, predicts outcome of estrogen
receptor (ER)–positive breast cancer patients treated with tamoxifen,
and mediates anti–estrogen resistance in mammary carcinoma.
Materials and Methods
Plasmid Constructs
The coding sequence for human TFF3 (GenBank accession number
NM_003226) was cloned into the mammalian expression vector
pIRESneo3 (Invitrogen, Carlsbad, CA), designated as pIRESneo3-TFF3.
The human TFF3 complementary DNA (cDNA) coding for the
mature peptide was cloned into the pGEX-4T1 vector (Amersham Bio-
sciences, Piscataway, NJ) in frame with the N-terminal glutathione-S-
transferase to generate pGEX-4T1-TFF3 plasmid for the expression of
glutathione-S-transferase–TFF3 fusion proteins in Escherichia coli.
To generate small interfering RNA (siRNA) oligonucleotides target-
ing TFF3, the DNA sequence AAACAACGGTGCATAAATGAG was
selected to construct an siRNA expression plasmid using the pSilencer
2.1-U6 hygro vector (Ambion, Austin, TX) according to the manufac-
turer’s protocol. The resultant vector was designated as pSilencer-TFF3.
The control siRNA plasmid (pSilencer-control) encodes an siRNA that
has no significant sequence similarity to human gene sequences.
Cell Culture
Human mammary carcinoma cell lines MCF-7 and T47D were ob-
tained from the American Type Culture Collection (ATCC, Manassas,
VA) and cultured in conditions as recommended. MCF-7 cells were
stably transfected with pIRESneo3-TFF3 or pIRESneo3 plasmids using
FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN).
After 4 weeks of selection in the medium containing 800 μg/ml G418
(Invitrogen), pooled stable transfectants were designated as MCF7-
TFF3 and MCF7-Vec, respectively. Similarly, MCF-7 cells were stably
transfected with pSilencer-TFF3 or pSilencer-control plasmids and then
selected in themedium containing 100 μg/ml hygromycin B (RocheDi-
agnostics) to obtain MCF7-siTFF3 and MCF7-siCK cells, respectively.
Reagents
β-Estradiol (E2), tamoxifen, and fulvestrant were purchased from
Sigma-Aldrich (St Louis, MO). BCL-2 inhibitor YC137 was purchased
from Calbiochem (San Diego, CA).
Semiquantitative Reverse Transcription–Polymerase Chain
Reaction and Quantitative Polymerase Chain Reaction
Semiquantitative reverse transcription–polymerase chain reac-
tion (RT-PCR) and quantitative PCR (qPCR) were performed as
described previously [27]. The primer sequences used for semiquanti-
tative RT-PCR and qPCR are listed in Tables W1 andW2, respectively.
Microarray Data Sets and Survival Analysis of ER-Positive
Breast Cancer Patients Treated with Tamoxifen
TFF3 gene expression characteristics in primary human breast
tumors were examined by microarray analysis in a cohort of 68 ER-
positive cases treated by surgery and/or radiation followed by adjuvant
tamoxifen monotherapy. This cohort represents a subset of the previ-
ously published Uppsala cohort [28] for which the microarray data set
is accessible at the Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/) through accession numberGSE3494. Briefly, themicro-
array data were processed using the MAS5.0 algorithm (Affymetrix
AGCC software), scaled to a mean target signal intensity of 500,
and log2-transformed. Using the probe set corresponding to the TFF3
transcript (204623_at), breast cancer cases were divided by TFF3
transcript levels into “low” (below mean) and “high” (above mean) gene
expression groups or into three expression groups based on expression
tertiles (lowest 33% n = 23, middle 33% n = 22, highest 33% n = 23),
then group survival characteristics were compared by Kaplan-Meier
analysis (Sigma Plot 11.0; Systat Software Inc., San Jose, CA). Three
survival end points were considered: 1) distant metastasis-free survival
1042 Trefoil Factor-3 Mediates Anti-Estrogen Resistance Kannan et al. Neoplasia Vol. 12, No. 12, 2010
(DMFS), with an event defined as breast cancer metastasis to a distant
organ site; 2) disease-specific survival, with an event defined as death
owing to breast cancer; and 3) disease-free survival, with an event de-
fined as a local, regional, or distant recurrence.
Meta-analysis of Breast Cancer Microarray Data Sets
The method for meta-analysis of breast cancer microarray data sets
to determine TFF3 expression and ER status in breast cancer patients
is described in the Supplementary Data.
Luciferase Reporter Assay
MCF-7 cells were plated in six-well plates and cultured in phenol
red–free RPMI medium supplemented with 10% charcoal-stripped
fetal bovine serum (CS-FBS) for 72 hours before transfection. Total
DNA 1 μg per well containing 0.5 μg of pGL2-ERE-luciferase plas-
mids and 0.5 μg of pcDNA3-β-galactosidase reporter plasmids were
transfected using FuGENE 6 reagent. After 24 hours, cells were then
treated with either DMSO or 10 nM E2 in 1% CS-FBS for another
24 hours. The luciferase reporter assay was performed using Luciferase
Assay System (Promega, Madison, WI) following the manufacturer’s
protocols. The luciferase values were normalized for β-galactosidase
activity, which was determined using β-galactosidase Enzyme Assay
System (Promega).
Production of Recombinant Human TFF3 and Generation of
TFF3 Polyclonal Antibody
The recombinant mature human TFF3 (rhTFF3) protein was ex-
pressed from pGEX-4T1-TFF3 plasmid in E. coli and purified using
glutathione-S-transferase tag under nondenaturing conditions and was
subsequently used to generate a rabbit TFF3 polyclonal antibody
(TFF3-pAb) as described previously [25].
Western Blot Analysis
Cells were grown to 70% to 80% confluence, then serum starved
overnight before lysed in the fresh lysis buffer (2% SDS, 20% glycerol,
60 mM Tris-HCl pH 6.8) supplemented with complete protease in-
hibitor tablets (Roche Diagnostics). The whole cell lysate was soni-
cated followed by centrifugation at 10,000g for 10 minutes. The
supernatant was collected, and protein concentration was determined
by Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA).
Protein samples were boiled for 5 minutes in the presence of 0.1 mM
dithiothreitol. Sodium dodecylsulfate (SDS)–polyacrylamide gel elec-
trophoresis (PAGE) Western blot analysis was performed as described
previously [29] using the following antibodies: mouse BCL-2 mono-
clonal antibody (BD Pharmingen, San Diego, CA), rabbit BAX poly-
clonal antibody (Calbiochem, San Diego, CA), mouse β-ACTIN
monoclonal antibody (Sigma-Aldrich). Proteins were visualized using
horseradish peroxidase–conjugated secondary antibody with enhanced
chemiluminescence. The image was scanned by GS-800 calibrated
densitometer and analyzed by software Quantity One (Bio-Rad Labo-
ratories, Hercules, CA).
Cell Function Assays
Total cell number, apoptosis assay using Hoechst 33258 staining,
bromodeoxyuridine (BrdU) incorporation, 96-well colony formation
in soft agar assay, three-dimensional Matrigel assay, transwell migra-
tion, and invasion assays were performed as previously described
[30]. Apoptosis was also assessed using fluorescein isothiocyanate–
conjugated annexin V and propidium iodide (PI) double staining.
After serum deprivation or treatment with 200 μg/ml TFF3-pAb or
rabbit IgG (Sigma) in 0.5% FBS for 24 hours, cells were washed with
PBS and labeled using Annexin V–FLUOS staining kit (Roche Diag-
nostics) according to the manufacturer’s instructions and analyzed
by fluorescence microscopy. For 3-(4,5-dimethylathiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) cell viability assay, 3 × 103 cells
per well were plated in 175 μl of culture medium containing 10% FBS
or 0.5% FBS in a 96-well plate, and 4 mg/ml TFF3-pAb or rabbit
IgG at the volume of 25 μl was added into each well. After incuba-
tion for 3 days, cell viability was measured by MTTassay as described
previously [31].
Cell Cycle Analysis
MCF7-Vec and MCF7-TFF3 cells were cultured in serum-free me-
dium for 24 hours, trypsinized, fixed in ice-cold 80% ethanol, and
stored in −20°C. Fixed cells were incubated with 1% Nonidet-P40/PBS
solution containing 4′,6-diamidino-2-phenylindole (DAPI, 1 μg/ml)
for 15 minutes at room temperature before being assessed by BD
FACSAriaII flow cytometer (BD Biosciences, Rockville, MD). Data
were analyzed using BD FACSDIVA software.
Tumor Xenografts in Nude Mice
TFF3-pAb treatment in tumor xenografts was performed essen-
tially as described previously [25]. For the study of tamoxifen treat-
ment in tumor xenografts, MCF7-Vec and MCF7-TFF3 xenografts
were established in 3- to 4-week-old BALBc athymic nude mice
(Shanghai Slaccas Co, Shanghai, China) supplemented with 0.72 mg
of E2 pellets (Innovative Research, Sarasota, FL) as previously de-
scribed [30]. On day 10 after inoculation (tumor reached the size of
80 mm3 approximately), mice were randomized to receive either con-
tinued estrogen supplementation or estrogen plus 5 mg of tamoxifen
base pellet (Innovative Research; n = 6 per group). Tumor volumemea-
surement, evaluation of tumor proliferation by BrdU incorporation
and apoptosis by terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling assay, and histologic staining with hematoxy-
lin and eosin were performed as described [30].
Statistics
All experiments were repeated at least three times. All numerical
data are expressed as mean ± SEM from a representative experiment
performed in triplicate. Data were analyzed using an unpaired two-
tailed t test or analysis of variance. P < .05 was considered significant.
Kaplan-Meier analyses were performed using Sigma Plot 11.0 soft-
ware, and the significance of the hazard ratios was ascertained by the
likelihood ratio test of P value.
Results
Forced Expression of TFF3 in MCF-7 Cells Increases
Proliferation and Survival
Using a previously published microarray data set (Gene Expression
Omnibus accession number GSE3494) [28], we analyzedTFF3mRNA
expression in breast cancer of 251 patients to determine the clinical
relevance of TFF3 expression in breast cancer. Kaplan-Meier analy-
sis demonstrated a highly significant correlation of increased TFF3
mRNA expression in breast cancer to decreased DMFS (P = .005; Fig-
ure W1 and Supplementary Data).
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A cell model was therefore established to determine the functional
role of TFF3 in human mammary carcinoma cells. MCF-7 cells were
stably transfected with a TFF3 expression vector (designated as
MCF7-TFF3) or with the empty vector (designated as MCF7-Vec).
Increased expression of TFF3 protein in MCF7-TFF3 cells compared
withMCF7-Vec cells was verified byWestern blot analysis (Figure 1A).
Forced expression of TFF3 in MCF-7 cells increased the total cell
number in monolayer in both serum-depleted (Figure 1B) and serum-
replete (Figure 1C ) conditions. Increased cell number is achieved by
increased cell proliferation and/or decreased cell death. Forced expres-
sion of TFF3 increased S-phase entry as assessed by BrdU incorpora-
tion (Figure 1D). Concordantly, cell cycle profiles determined by flow
cytometric analysis revealed a higher percentage of MCF7-TFF3 cells
in S-phase (25%) than MCF7-Vec cells (15%) in serum-free medium
(Figure W2A and Supplementary Data). The effect of forced expres-
sion of TFF3 on apoptosis after serum deprivation for 24 hours was
determined by two methods. Fluorescent microscopic analysis of cell
nuclear staining patterns with Hoechst 33258 dye demonstrated that
forced expression of TFF3 reduced apoptosis compared with vector
cells (Figure 1E ). Annexin Vand PI double staining revealed that both
early (annexin V–positive and PI-negative) and late apoptosis (annexin
V–positive and PI-positive) were decreased in MCF7-TFF3 cells
(3% and 2%, respectively) compared with MCF7-Vec cells (5% and
3%, respectively; Figure W2B and Supplementary Data). We further
examined the effect of forced expression of TFF3 on cell survival after
treatment with doxorubicin, an inhibitor of topoisomerase II. Cell
viability after treatment with doxorubicin at various concentrations
for 3 days was determined by MTT assay. A significant enhancement
of cell viability was observed in MCF7-TFF3 cells compared with
MCF7-Vec cells in the presence of doxorubicin (Figure W2C and Sup-
plementary Data).
qPCR analysis (Table W3 and Supplementary Data) demonstrated
that forced expression of TFF3 in MCF-7 cells dramatically increased
the expression levels of cell cycle–related genes including CCNA1 (Cyclin
A1), which promotes G1- to S-phase transition [32], and CDK1 (Cyclin-
dependent kinase 1), which plays an essential role in S-phase entry and
mitosis [33]. Moreover, a significant decrease in the mRNA level of
CDKN1A (p21), a negative regulator of cell growth [34], was observed
in MCF7-TFF3 cells.
The members of the Bcl-2 family were also differentially regulated
by TFF3. BCL-2 mRNA level was increased by forced expression of
TFF3 in MCF-7 cells, whereas BAX, a cell death mediator inducing
mitochondrial damage [35], was significantly downregulated. In addi-
tion, decreasedmRNA levels ofCASP7 (Caspase7 ) andHTATIP2 (also
known as TIP30, CC3, a metastasis suppressor that inhibits metastasis
and promotes apoptosis) were observed in MCF-7 cells consequent
to forced expression of TFF3. Therefore, forced expression of TFF3
promoted proliferation and reduced apoptosis of human mammary
carcinoma cells, which was associated with the differential regulation
of cell cycle and apoptosis-related genes.
Figure 1. Forced expression of TFF3 in MCF-7 cells increases cell proliferation and survival, and enhances cell migration and invasion.
MCF-7 cells were stably transfected with the expression plasmid containing TFF3 cDNA (designated as MCF7-TFF3) or the empty vector
(designated as MCF7-Vec) as control. (A) Western blot analysis of TFF3 protein level in cell lysates of MCF7-Vec and MCF7-TFF3 cells.
β-ACTIN was used as a loading control for cell lysates. (B and C) Total cell number assays: MCF7-Vec and MCF7-TFF3 cells were cultured
in the medium containing 0.2% FBS (B) or 10% FBS (C). Cell numbers were counted at the indicated time points. (D) BrdU incorporation
assay: The percentages of BrdU-positive cell nuclei relative to the total number of cells in MCF7-Vec and MCF7-TFF3 cells were deter-
mined. (E) Apoptosis assay: MCF7-Vec and MCF7-TFF3 cells were cultured in serum-free medium for 24 hours, and cell apoptosis was
measured by fluorescent microscopic analysis of nuclear staining patterns with Hoechst 33258 dye. (F) Migration and invasion assays:
MCF7-Vec and MCF7-TFF3 cell migration after 24 hours and invasion after 48 hours in the transwell chambers. (G) Wound healing assay.
Bar, 100 μm in G. *P < .05. **P < .01.
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Forced Expression of TFF3 in MCF-7 Cells Promotes
Migration and Invasion
The effect of TFF3 on cell motility was examined by the transwell
migration and wound healing assays. Forced expression of TFF3 in
MCF-7 cells resulted in a 1.7-fold increased cell migration compared
with vector cells (Figure 1F ). Similarly, in the wound healing assay,
MCF7-TFF3 cells closed monolayer wounds significantly faster than
MCF7-Vec cells (Figure 1G ). Furthermore, in the transwell chambers
coated withMatrigel, the invasive capacity ofMCF7-TFF3 cells was en-
hanced 1.6-fold compared with the respective control cells (Figure 1F ).
qPCR analysis (Table W3 and Supplementary Data) concordantly
demonstrated that MCF7-TFF3 cells expressed lower levels of CDH1
and CTNNG, which encode E-CADHERIN and γ-CATENIN, re-
spectively. γ-CATENIN mediates E-CADHERIN–dependent inter-
cellular adhesions. Decreased expression of E-CADHERIN and
γ-CATENIN is thought to contribute to metastasis of human mam-
mary carcinoma [36,37]. In contrast, increased expression of FN1,
which encodes the extracellular matrix protein FIBRONECTIN,
and VIM, which encodes the intermediate filament VIMENTIN, was
observed in MCF7-TFF3 cells relative to MCF7-Vec cells. Decreased
expression of epithelial markers E-CADHERIN and γ-CATENIN
and induction of mesenchymal markers FIBRONECTIN and
VIMENTIN are associated with epithelial-mesenchymal transition [38].
Forced Expression of TFF3 Enhances Oncogenicity of
MCF-7 Cells
Anchorage-independent growth is a hallmark of oncogenic trans-
formation. We have previously demonstrated that transient transfec-
tion of TFF3 conferred the ability of capacity for immortalized but
otherwise normal human mammary epithelial cells to form colonies
in soft agar and also resulted in an increase in soft agar colony forma-
tion in mammary carcinoma cells [26]. Stable forced expression of
TFF3 in MCF-7 cells also stimulated anchorage-independent growth
as indicated by increased colony formation (Figure 2A), foci formation
(Figure 2B), and total cell number in suspension culture (Figure 2C )
compared with MCF7-Vec cells.
We subsequently determined the involvement of BCL-2 in TFF3-
stimulated anchorage-independent growth. We observed that, concor-
dant with the qPCR results described above, forced expression of
TFF3 markedly increased the protein level of BCL-2 and decreased
the expression of BAX (Figure 2D). BCL-2 specific inhibitor YC137
reduced soft agar colony formation by MCF7-Vec cells in a dose-
dependent manner. YC137 also abrogated TFF3-enhanced colony
formation in soft agar, suggesting that TFF3-stimulated anchorage-
independent growth is BCL-2–dependent (Figure 2E ).
We further evaluated the effect of forced expression of TFF3 on cell
growth in the three-dimensional culture of laminin-rich extracellular
matrix gels (Matrigel; BD Biosciences, Franklin Lakes, NJ). The col-
onies formed by MCF7-TFF3 cells were significantly larger and ap-
peared more invasive compared with those formed by MCF7-Vec
cells (Figure 2F ). Consistent with the in vitro analyses, forced expres-
sion of TFF3 also promoted MCF-7 cell–derived xenograft growth
(see below).
Depletion of TFF3 by siRNA Reduces Oncogenicity of
Mammary Carcinoma Cells
An siRNA construct targeting TFF3 or a scrambled siRNA as con-
trol was stably transfected into MCF-7 cells (designated as MCF7-
siTFF3 and MCF7-siCK, respectively). Figure 3A demonstrated that
the TFF3 protein level was efficiently decreased inMCF7-siTFF3 cells
Figure 2. Forced expression of TFF3 enhances oncogenicity of MCF-7 cells. Anchorage-independent growth was evaluated by colony
formation in soft agar (A), foci formation (B), and growth in suspension culture (C) in themedium supplementedwith 10%FBS. (D)Western
blot analysis of BAX and BCL-2 protein levels in cell lysates of MCF7-Vec and MCF7-TFF3 cells. β-ACTIN was used as a loading control for
cell lysates. (E) Colony formation in soft agar: MCF7-Vec and MCF7-TFF3 cells were seeded in 0.35% agar in a 96-well plate and treated
with BCL-2 inhibitor YC137 at the indicated concentrations for 10 days. (F) Three-dimensional Matrigel assay: MCF7-Vec and MCF7-TFF3
cells were cultured in 4% Matrigel in 10% FBS medium for 7 days. Bar, 100 μm in A, B, and F. *P < .05. **P < .01.
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compared with MCF7-siCK cells. siRNA-mediated depletion of
TFF3 produced a 59% decrease in anchorage-independent growth
(Figure 3B) and a 50% decrease in cell growth in three-dimensional
Matrigel (Figure 3C ). Furthermore, depletion of TFF3 reduced
MCF-7 cell migration and invasion by 41% and 44%, respectively
(Figure 3D).
Functional Antagonism of TFF3 by TFF3 Polyclonal Antibody
Reduces Cell Viability In Vitro and Inhibits
Xenograft Growth
The rhTFF3 protein was produced under nondenaturing condi-
tions. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) determined the presence of dimeric rhTFF3 under non-
reducing conditions (∼14 kDa) and monomeric rhTFF3 under reduc-
ing conditions (∼7 kDa; Figure W3A and Supplementary Data). A
polyclonal antibody against rhTFF3 was generated in rabbits and
was affinity-purified against antigen. ELISA confirmed that TFF3-
pAb bound to rhTFF3 with high affinity (K d = 53.3 pM) and at the de-
tection limit of 10 pg (Figure W3, B and C , and Supplementary Data).
Western blot analysis confirmed that TFF3-pAb did not exhibit cross-
reactivity with rhTFF1 protein (Figure W3D and Supplementary Data).
The effects of TFF3-pAb on mammary carcinoma cell growth were
evaluated in MCF-7 and T47D cells. T47D cells have previously been
reported to express TFF3 [23], and we have confirmed this observation
by Western blot analysis (data not shown). A significant reduction of
cell viability was observed on TFF3-pAb treatment in serum-depleted
conditions (0.5% FBS) with 90% and 43% inhibition compared to
treatment with nonspecific rabbit IgG in MCF-7 and T47D cells, re-
spectively (Figure 4A). Under serum-replete conditions (10% FBS),
TFF3-pAb reduced MCF-7 cell viability by 31% and T47D cell via-
bility by 25% (Figure 4A) compared with control rabbit IgG. Notably,
treatment with TFF3-pAb resulted in a significant increase in apopto-
tic cell death in both MCF-7 and T47D cells as measured by Hoechst
33258 dye (Figure 4B) and annexin V and PI double staining (Fig-
ure W3E and Supplementary Data). In addition, TFF3-pAb also re-
duced cell growth in three-dimensionalMatrigel by 53% inMCF-7 cells
and 42% in T47D cells compared with control rabbit IgG (Figure 4C).
We further examined the effect of TFF3-pAb treatment on the
growth of human mammary carcinoma xenografts in nude mice.
TFF3-pAb, dosed 16 days after MCF-7 cell implantation and there-
after daily for 2 weeks, produced tumor growth arrest (Figure 4D).
Histologic analyses showed large necrotic fields surrounded by inflam-
matory granuloma. The residual tumor cells were isolated from normal
mouse tissue by a vascular fibrous capsule (Figure 4E ). To investigate
potential adverse effects of TFF3-pAb treatment, we examined the
tissue integrity in several organs including liver, lung, intestine, kidney,
and stomach of both TFF3-pAb and nonspecific rabbit IgG-treated
mice. No histologic alterations were identified between the two groups
(Figure W4 and Supplementary Data). Therefore, TFF3-pAb, as a
single agent, effectively produced growth arrest of mammary carci-
noma xenografts.
TFF3 Expression Correlates to Poor Outcome in ER-Positive
Breast Cancer Patients Treated with Tamoxifen
TFF3 is an estrogen-regulated gene [23]. We therefore performed a
meta-analysis to determine the association ofTFF3 expression with ER
status in breast cancer patients. We analyzed 15 breast cancer micro-
array data sets available in the cancer microarray database Oncomine
(www.oncomine.org) and identified a strong correlation of TFF3
mRNA expression with ER-positive status in mammary carcinoma
Figure 3. Depletion of TFF3 by siRNA inhibits anchorage-independent growth and invasiveness of mammary carcinoma cells. (A)Western
blot analysis of the efficiency of siRNA-mediated depletion of TFF3 protein in MCF-7 cells. β-ACTIN was used as a loading control for
cell lysates. (B) Colony formation in soft agar: MCF7-siCK and MCF7-siTFF3 cells were seeded in 0.35% agar and cultured for 10 days.
(C) Three-dimensional Matrigel assay: MCF7-Vec and MCF7-TFF3 cells were cultured in 4% Matrigel in 10% FBS medium for 7 days.
(D) Migration and invasion assays: MCF7-siCK and MCF7-siTFF3 cell migration after 24 hours and invasion after 48 hours in the transwell
chambers. Bar, 100 μm in B and C. *P < .05. **P < .01.
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(P < .0001, t value of −1.45 with 95% confidence interval of −1.78 to
−1.11; Figure W5 and Supplementary Data).
We further examined whether TFF3 expression would predict the
outcome of ER-positive breast cancer patients treated with anti-
estrogens. Kaplan-Meier analysis of 68 ER-positive breast cancer
patients treated with tamoxifen demonstrated a highly significant
correlation of increased TFF3 mRNA expression to decreased DMFS
(P = .00002; Figure W6A and Supplementary Data) and disease-
specific survival (P = .001; Figure W6B and Supplementary Data).
TFF3 expression was also strongly associated with disease-free survival
(P = .00003; Figure W6C and Supplementary Data). To highlight the
significant association of TFF3 expression with poor DMFS outcome,
we further split the cohort into three groups: lowest 33% (n = 23),
intermediate 33% (n = 22), and highest 33% (n = 23) of the expression
level of TFF3 (Figure W6D and Supplementary Data). The groups
with the intermediate and highest TFF3 expression have a particularly
poor outcome in comparison to those with the lowest TFF3 expres-
sion (P = .008).
TFF3 Enhances ER Transcriptional Activity and Function
Because of the observed correlation between TFF3 expression and
ER status, we subsequently investigated a potential functional inter-
action between TFF3 and ER signaling pathways. We first measured
ER transcriptional activity with a luciferase reporter containing the
ER element (ERE). MCF7-TFF3 cells exhibited a 2.8-fold higher
basal ER transcriptional activity compared with MCF7-Vec cells. E2
Figure 4. Neutralization of TFF3 by TFF3 polyclonal antibody reduces viability of mammary carcinoma cells and inhibits xenograft growth.
(A) MCF-7 and T47D cells were treated with 500 μg/ml control rabbit IgG or TFF3-pAb in either 0.5% FBS or 10% FBS medium for 3 days.
Cell viability was measured by MTT assay as described in Materials and Methods. (B) Apoptotic cell death was assessed by fluorescent
microscopic analysis of cell nuclear staining patternswith Hoechst 33258 dye after treatment for 24 hours. (C) Three-dimensionalMatrigel:
MCF-7 cells and T47D cells were cultured in 4% Matrigel in 10% FBS medium containing 500 μg/ml nonspecific rabbit IgG or TFF3-pAb
for 7 days. MCF-7 xenografts in immunodeficient mice were treated with either control rabbit IgG or TFF3-pAb for 14 days. (D) Tumor
growth of TFF3-pAb–treated mice and control rabbit IgG–treated mice. (E) Histologic staining of the tumors with hematoxylin and eosin.
Arrow A indicates inflammatory granuloma; arrow B, necrotic tissue within the tumor; and arrow C, residual tumor. Bar, 100 μm in C.
*P < .05. **P < .01.
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increased ERE luciferase activity and forced expression of TFF3 addi-
tively increased ER transcriptional activity with E2 (Figure 5A). TFF1 is
a classic estrogen-responsive gene [39]. qPCR analysis demonstrated
that forced expression of TFF3 increased TFF1mRNA level compared
with vector cells (Figure 5B). We further examined the effect of forced
expression of TFF3 on cell proliferation in monolayer and anchorage-
independent growth under estrogen-deprived or estrogen-replete condi-
tions. In the absence of estrogen, forced expression of TFF3 resulted in
increased cell number in monolayer (Figure 5C ) and colony formation
in soft agar (Figure 5D) compared with vector cells. E2 promoted cell
growth both inmonolayer culture and in soft agar, and forced expression
of TFF3 enhanced E2-stimulated cell proliferation under both culture
conditions (Figure 5, C and D).
Forced Expression of TFF3 Reduces Anti–Estrogen Sensitivity
of MCF-7 Cells in a BCL-2–Dependent Manner
As our data indicated that TFF3 promoted estrogen-independent
growth, we next examined the effect of TFF3 on the cellular response
to antiestrogens in MCF-7 cells. Figure 6, A and B, show a dose-
dependent decrease in colony formation in soft agar inMCF7-Vec cells
after tamoxifen and fulvestrant treatment. Forced expression of TFF3
significantly abrogated the inhibitory effect of both antiestrogens on
anchorage-independent growth. Similarly, MCF7-TFF3 cells displayed
a reduced sensitivity to antiestrogen treatment in three-dimensional
Matrigel with 51% and 41% greater growth relative toMCF7-Vec cells
in the presence of tamoxifen and fulvestrant, respectively (Figure 6C ).
We have shown that TFF3 increased BCL-2 expression to promote
anchorage-independent growth. To determine whether BCL-2 is also
involved in anti–estrogen resistance stimulated by TFF3, we examined
the anchorage-independent growth of MCF7-Vec and MCF7-TFF3
cells in the presence of the BCL-2 inhibitor YC137 alone or in com-
bination with tamoxifen or fulvestrant. As shown in Figure 6D, treat-
ment of YC137 eliminated the survival advantage of MCF7-TFF3
cells in response to tamoxifen or fulvestrant, suggesting that decreased
anti–estrogen sensitivity produced by forced expression of TFF3 is
mediated by increased BCL-2 expression.
Forced Expression of TFF3 Reduces Tamoxifen Sensitivity of
MCF-7 Cells In Vivo
We next investigated the effect of forced expression of TFF3 on
tamoxifen sensitivity in a mouse xenograft model. MCF-7 xenografts
were grown for 10 days and subsequently treated with tamoxifen in the
presence of estrogen supplement. In the untreated groups, tumors
formed by MCF7-TFF3 cells were larger than those formed by
MCF7-Vec cells, indicating that TFF3 enhanced tumorigenicity
in vivo. Tamoxifen inhibited the growth of tumors derived from
Figure 5. Forced expression of TFF3 increases ER transcriptional activity in mammary carcinoma cells. (A) ERE-luciferase assay: MCF7-
Vec and MCF7-TFF3 cells were transiently cotransfected with of pGL2-ERE-luciferase plasmid and pcDNA3 β-galactosidase plasmids in
six-well plates in phenol red–free RPMImedium supplementedwith 1%CS-FBS. Twenty-four hours later, the cells were treatedwith either
DMSO (vehicle) or 10 nM E2 for another 24 hours. The cell lysates were collected and assessed for luciferase activity. (B) MCF7-Vec and
MCF7-TFF3 cells were treated with either DMSO (vehicle) or 10 nM E2 in phenol red–free RPMI medium supplemented with 1% CS-FBS
for 24 hours before RNA isolation. TFF1 mRNA levels were measured by qPCR. (C) Total cell number: MCF7-Vec and MCF7-TFF3 cells
were cultured in 10% FBS, 10% CS-FBS, or 10% CS-FBS containing 10 nM E2 for 48 hours. (D) Colony formation in soft agar: MCF7-Vec
and MCF7-TFF3 cells were seeded in 0.35% agar in a 96-well plate and treated with vehicle (Veh) or 10 nM E2 in 10% CS-FBS medium for
10 days. *P < .05, **P < .01 compared with vector control group for the same treatment.
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MCF7-Vec cells as expected. In contrast, forced expression of TFF3
attenuated the growth-inhibitory effect of tamoxifen, producing a
tumor growth rate comparable with that observed in untreated
MCF7-Vec tumors (Figure 7A).
Tamoxifen suppressed BrdU incorporation and increased apoptosis
in MCF7-Vec tumors. MCF7-TFF3 tumors exhibited 1.7-fold higher
BrdU incorporation (Figure 7B) and 45% less apoptosis (Figure 7C )
relative to MCF7-Vec cells after tamoxifen treatment, suggesting that
forced expression of TFF3 reduced tamoxifen efficacy in xenografts by
preventing cell cycle arrest and providing protection from apoptosis.
Histologic examination revealed that MCF7-TFF3 tumors contained
pleomorphic cells with irregular hyperchromatic nuclei and scanty cyto-
plasm compared with well-differentiated MCF7-Vec tumor cells
(Figure 7D). Moreover, MCF7-TFF3 tumors were larger with ill-de-
fined margins to the surrounding tissues and evident vascular and peri-
neural invasion. Tamoxifen treatment resulted in a smaller tumor lesion
in MCF7-Vec tumors, whereas MCF7-TFF3 tumors still exhibited in-
vasive tendencies (Figure 7D).
Depletion of TFF3 by siRNA or Inhibition of TFF3 by
Antibody Increases Anti–Estrogen Sensitivity in Mammary
Carcinoma Cells
Tamoxifen and fulvestrant inhibited colony formation in soft agar
of control siRNA transfected cells (Figure 8, A and B). Similar inhib-
itory effects of tamoxifen and fulvestrant were observed in three-
dimensional Matrigel (Figure 8C ). Depletion of TFF3 by siRNA
increased the sensitivity of MCF-7 cells to both tamoxifen and fulves-
trant, resulting in reduced growth in soft agar (Figure 8, A and B) and
in three-dimensional Matrigel (Figure 8C ). Consistent with the effect
of depletion of TFF3 by siRNA, TFF3-pAb also enhanced the growth-
inhibitory effect of tamoxifen. As shown in Figure 8D, TFF3-pAb re-
duced MCF-7 cell growth in three-dimensional Matrigel by 78.8%,
whereas tamoxifen produced a 52% growth inhibition. The combina-
tion of TFF3-pAb with tamoxifen produced a total 95% inhibition
of cell growth in three-dimensional Matrigel.
Inhibition of TFF3 Improves Tamoxifen Sensitivity in
Tamoxifen-Resistant Cells
We previously have generated a tamoxifen-resistant MCF-7 cell line
(designated as TAMR) and a control tamoxifen-sensitive MCF-7 cell
line (designated as TAMS) [40]. In an attempt to determine the role of
TFF3 in acquired tamoxifen resistance, we examined TFF3 expression
in TAMS and TAMR cells. In the absence of tamoxifen, both the
mRNA and protein levels of TFF3 were higher in TAMR cells com-
pared with TAMS cells (Figure 8E ). Paradoxically, tamoxifen increased
TFF3 expression at both mRNA and protein levels in TAMS cells, and
TAMR cells exhibited further elevated TFF3 expression in response to
tamoxifen (Figure 8E ).
Figure 6. Forced expression of TFF3 reduces anti–estrogen sensitivity in mammary carcinoma cells. (A, B) Colony formation in soft agar:
MCF7-Vec and MCF7-TFF3 cells were seeded in 0.35% agar in a 96-well plate and treated with tamoxifen (TAM) or fulvestrant (Fulv) in
10% FBS at the concentrations indicated for 10 days. (C) Three-dimensional Matrigel: MCF7-Vec and MCF7-TFF3 cells were seeded in
4% Matrigel in 10% FBS medium and treated with vehicle (Veh) or 1 μM tamoxifen or 10 nM fulvestrant for 7 days. (D) Colony formation
in soft agar: MCF7-Vec and MCF7-TFF3 cells were seeded in 0.35% agar and treated with BCL-2 inhibitor YC137 at 1 or 5 μM alone or in
combination with 1 μM tamoxifen or 10 nM fulvestrant for 10 days. *P< .05, **P< .01, ***P< .001 compared with vector control group for
the same treatment.
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To investigate the function of TFF3 in TAMR cells, TAMR cells
and TAMS cells were treated with tamoxifen, TFF3-pAb, or tamoxi-
fen plus TFF3-pAb, and cell growth in three-dimensional Matrigel was
measured. Tamoxifen did not significantly affect TAMR cell growth,
whereas TFF3-pAb alone suppressed the growth of TAMR cells by
36% (Figure 8F ). Combined treatment with TFF3-pAb and tamoxi-
fen resulted in 64% growth inhibition, producing a percentage reduc-
tion similar to that observed in TAMS cells treated with tamoxifen.
Discussion
There is a growing body of evidence that supports a role for TFF3 in
oncogenic transformation and neoplastic progression of mammary
carcinoma. We herein reported a strong correlation of TFF3 mRNA
expression with poor survival outcome not only in the cohort of breast
cancer patients treated with tamoxifen but also in the wider population
of patients with breast cancer. In support of the clinical relevance of
elevated TFF3 expression in breast cancer, we further demonstrated
Figure 7. Forced expression of TFF3 reduces tamoxifen sensitivity of mammary carcinoma cells in vivo. MCF7-Vec and MCF7-TFF3 cells
were implanted into the mammary fat pad of athymic nude mice. The tumor xenografts were treated with estrogen or estrogen plus
tamoxifen on day 10 after inoculation. (A) The growth curves of MCF7-Vec and MCF7-TFF3 tumors in the presence and the absence of
tamoxifen (TAM). (B and C) Evaluation of tumor proliferation by nuclear BrdU incorporation (B) and apoptosis by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling assay (C) in MCF7-Vec and MCF7-TFF3 xenografts. (D) Histologic staining of representative
tumors with hematoxylin and eosin. Circle A indicates the region of perineural invasion; circles B and C, regions of vascular invasion. Bar,
100 μm in D. *P < .05, **P < .01, ***P < .001 compared with vector control group for the same treatment.
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that TFF3 stimulated oncogenicity and invasiveness of mammary car-
cinoma cells and was involved in anti–estrogen resistance both in vitro
and in vivo.
TFF3 is a potent survival factor for mammary carcinoma cells.
Forced expression of TFF3 significantly reduced serum deprivation
and doxorubicin-induced apoptosis in MCF-7 cells. Concordantly,
qPCR analyses revealed that TFF3 modulated the expression of some
key apoptosis-related genes. We further demonstrated that TFF3-
stimulated anchorage-independent growth is BCL-2–dependent. The
antiapoptotic action of BCL-2 has been well established [41]. It is un-
likely that up-regulation of BCL-2 is the sole mechanism accounting
for the prosurvival effect of TFF3. For example, the expression of BAX,
a proapoptotic member of the BCL-2 family, was dramatically reduced
by TFF3. Moreover, other survival signaling pathways may also con-
tribute to TFF3-stimulated oncogenicity inmammary carcinoma cells.
TFF3 has been reported to activate mitogen-activated protein kinase
Figure 8. Depletion of TFF3 by siRNA or inhibition of TFF3 function by antibody increases anti–estrogen sensitivity in MCF-7 cells and
improves tamoxifen sensitivity in tamoxifen-resistant cells. (A and B) Colony formation in soft agar: MCF7-siCK and MCF7-siTFF3 cells
were seeded in 0.35% agar and treated with tamoxifen (TAM) and fulvestrant (Fulv) in 10% FBS at the concentrations indicated for
10 days. (C) Three-dimensional Matrigel: MCF7-siCK and MCF7-siTFF3 cells were seeded in 4% Matrigel and treated with vehicle (Veh)
or 1 μM tamoxifen or 10 nM fulvestrant for 7 days. (D) Three-dimensional Matrigel: MCF-7 cells were seeded in 4% Matrigel and treated
with 1 μM tamoxifen alone or in combination with 500 μg/ml TFF3-pAb or control rabbit IgG for 7 days. (E) TAMS and TAMR cells were
cultured in phenol red–free RPMI medium containing 10% CS-FBS for 3 days and then treated with either vehicle or 1 μM tamoxifen for
24 hours. TFF3 expression was determined by semiquantitative RT-PCR andWestern blot analysis. (F) TAMS and TAMR cells were seeded
in 4%Matrigel in 10%CS-FBSmedium and treatedwith 1 μM tamoxifen alone or in combinationwith 500 μg/ml TFF3-pAb or control rabbit
IgG for 7 days. *P< .05, **P< .01, ***P< .001 comparedwith vector control group for the same treatment (A, B, and C) or comparedwith
control IgG and vehicle-treated group (D and F).
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[24], phosphatidylinositol-3-kinase–Akt [16,42], signal transducer
and activator of transcription 3 [13], and nuclear factor kappa B
(NF-κB) [43] survival pathways. Interestingly, BCL-2 seems to be
a common final mediator as BCL-2 expression is regulated by all
of the above-mentioned signaling pathways [44,45]. Moreover, we
demonstrated herein functional cross talk between the TFF3 and ER
pathways. Forced expression of TFF3 increased ER transcriptional
activity and enhanced the estrogenic response. Given the prosurvival
effect of ER signaling in mammary carcinoma cells, TFF3-mediated
enhancement of ER function may be considered as one potential
mechanism producing TFF3-stimulated cell survival.
The fundamental contribution of growth factor–driven signaling
pathways to the development of either de novo or acquired endocrine
resistance has been widely recognized. In this study, we identified
TFF3 as a novel growth factor involved in anti–estrogen resistance.
As an estrogen-inducible gene, TFF3 expression is stimulated by estro-
gen treatment [23]. Paradoxically, the selective ER modulator tamoxi-
fen also increased TFF3 expression level in the ER-positive mammary
carcinoma cells, which is consistent with previously published data
[23]. The mechanisms of the agonist action of tamoxifen remain un-
clear, although gene expression profiling has identified partial agonistic
activity of tamoxifen on 30% of E2-inducible genes [46]. Of particular
note is the fact that in TAMR cells, TFF3 expression was substantially
increased and further induced by tamoxifen. Functional antagonism
of TFF3 by antibody effectively inhibited cell growth and improved
tamoxifen sensitivity of TAMR cells. We therefore speculate that
tamoxifen-induced TFF3 expression may provide a survival advantage
in the presence of tamoxifen treatment and will contribute to both
intrinsic and acquired tamoxifen resistance.
Although the mechanisms by which growth factor signaling path-
ways promote anti–estrogen resistance have not been fully elucidated,
cumulative experimental data suggest that activated growth factor sig-
naling pathways either cross talk with ER signaling pathway resulting
in ligand-independent or tamoxifen-induced ER activation or func-
tion as alternative mitogenic and/or survival pathways, consequently
promoting anti–estrogen resistant tumor cell growth [47–49]. Our
data also suggested a potential functional interaction between TFF3
and ER signal transduction through which ER activation upregulated
TFF3 expression and TFF3 stimulation increased ER transcriptional
activity. Epidermal growth factor receptor (EGFR) and HER2 signal-
ing pathways have long been implicated in anti–estrogen resistance.
In support of TFF3-mediated anti–estrogen resistance, the potential
involvement of EGFR activation in the TFF3 signaling pathway has
been reported by several studies [16,42,50]. In addition, because in-
duction of cell apoptosis mediates the growth-inhibitory effect of anti-
estrogens, activation of cell survival pathways and protection from
apoptosis would attenuate anti–estrogen sensitivity [49,51]. We dem-
onstrated that TFF3-stimulated resistance to antiestrogens is mediated
by up-regulation of BCL-2 expression. The contribution of BCL-2 in
anti–estrogen-induced apoptosis and resistance to antiestrogen therapy
has been well studied in cell culture model [52–54], although
conflicting data were reported from clinical studies, which revealed a
correlation of decreased BCL-2 expression with reduced tamoxifen
sensitivity [51]. This may partially reflect the estrogenic regulation
of BCL-2 expression in estrogen-responsive tumors that are more
likely to respond to antiestrogen therapy [55]. As previously discussed,
BCL-2 is a common mediator of several survival signaling pathways.
Therefore, increased BCL-2 is probably a consequence of activation of
survival pathways, resulting from increased TFF3 expression.
Although TFF3 is an estrogen-responsive gene and its expression
level is positively correlated to ER status in humanmammary carcinoma,
there is growing evidence that a subset of ER-negative mammary
tumors also express high levels of TFF3 [56,57]. These mammary
tumors have been characterized by expression of androgen receptor
(AR) and HER2 and classified into molecular apocrine subtype [58].
Cross talk between AR and HER2 pathways have also been recently
elucidated in mammary carcinoma cell lines with molecular apocrine
features [57]. Whether the TFF3 signaling pathway contributes to AR
and HER2 cross talk and affects molecular apocrine mammary carci-
noma cell growth remains to be determined. Further investigation of
TFF3 function in ER-negative mammary carcinoma cell lines is there-
fore required to provide a more comprehensive understanding of
TFF3 actions in mammary carcinoma.
Herein we have identified TFF3 as a functionally and clinically
validated molecule involved in progression of human mammary car-
cinoma. Forced expression of TFF3 enhanced the oncogenicity, and
mediated anti–estrogen resistance, of mammary carcinoma cells. Con-
versely, inhibition of TFF3 by siRNA or antibody reduced the onco-
genicity of mammary carcinoma cells and increased the efficacy of
antiestrogens. Given low or undetectable TFF3 expression in nor-
mal mammary tissues and elevated expression of TFF3 in mammary
carcinoma [6], targeting of TFF3 may therefore represent a novel ther-
apeutic approach for breast cancer treatment with high specificity
and efficacy.
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Supplementary Data
Figure W1. TFF3 mRNA expression is correlated with decreased
DMFS in breast cancer patients. 251 breast cancer patients of the
Uppsala cohort were split into two groups: low TFF3 expression
(below mean) and high TFF3 expression (above mean). The DMFS
of these two groups was compared by Kaplan-Meier (K-M) analysis
as described in the Materials and Methods section.
Figure W2. Forced expression of TFF3 increases cell cycle entry and reduces apoptosis of human mammary carcinoma cells. (A) Cell
cycle analysis of MCF7-Vec and MCF7-TFF3 cells by DAPI staining after 24 hours of serum depletion. (B) Determination of early and
late apoptosis of MCF7-Vec and MCF7-TFF3 cells by annexin V (AV) and propidium iodide (PI) double staining. Both early apoptosis (AV+
PI−) and later apoptosis (AV+ PI+) are presented as the percentage of total cells. (C) Cell viability of MCF7-Vec and MCF7-TFF3 cells
after treatment with doxorubicin at various concentrations in 0.5% FBS for 3 days was determined by MTT assay. *P < .05, **P < .01.
Table W1. Sequences of Oligonucleotide Primers Used for Semiquantitative RT-PCR.
Genes Abbreviation Primer Sequence (5′-3′) Amplicon Size (bp)
Trefoil factor 3 TFF3 Forward GGCTGTGATTGCTGCCAG 125
Reverse GTGGAGCATGGGACCTTTAT
Beta-actin β-ACTIN Forward ATGATATCGCCGCGCTCG 580
Reverse CGCTCGGTGAGGATCTTCA
Table W2. Sequences of Oligonucleotide Primers Used for qPCR.
Genes Abbreviation Primer Sequence (5′-3′) Amplicon Size (bp)
v-akt murine thymoma viral oncogene homolog 1 AKT1 Forward GCACAAACGAGGGGAGTACAT 113
Reverse CCTCACGTTGGTCCACATC
v-raf murine sarcoma 3611 vial oncogene homolog 1 ARAF1 Forward CTTGCTGTCCTCCAGCTCT 124
Reverse CCGGTTGTTGCACTCCTT
Ataxia telangiectasia mutated ATM Forward TGGATCCAGCTATTTGGTTTGA 82
Reverse CCAAGTATGTAACCAACAATAGAAGAAGTAG
BCL2-antagonist of cell death BAD Forward CCCAGAGTTTGAGCCGAGTG 249
Reverse CCCATCCCTTCGTCGTCCT
BCL2-antagonist killer 1 BAK1 Forward GAACAGGAGGCTGAAGGGGT 307
Reverse TCAGGCCATGCTGGTAGACG
BCL2-associated X protein BAX Forward GGGTGGTTGGGTGAGACTC 199
Reverse AGACACGTAAGGAAAACGCATTA
B-cell CLL/lymphoma 2 BCL2 Forward TCCGCATCAGGAAGGCTAGA 113
Reverse AGGACCAGGCCTCCAAGCT
BCL2-like 1 BCL2L1 Forward ATGGCAGCAGTAAAGCAAGC 149
Reverse CGGAAGAGTTCATTCACTACCTGT
beta-Actin β-ACTIN Forward TTCCTGGGCATGGAGTC 84
Reverse CAGGTCTTTGCGGATGTC
Baculoviral IAP repeat-containing 5 BIRC5 Forward TCCACTGCCCCACTGAGAAC 76
Reverse TGGCTCCCAGCCTTCCA
Breast cancer 1, early onset BRCA1 Forward CATGCTGAAACTTCTCAACCAGAA 81
Reverse TGTAGGCTCCTTTTGGTTATATCATTC
Caspase 7, apoptosis-related cysteine peptidase CASP7 Forward AGTGACAGGTATGGGCGTTCG 274
Reverse GCATCTATCCCCCCTAAAGTGG
Cyclin A1 CCNA1 Forward AAACTACTAAAGTCTAAGGGAAA 170
Reverse CTTCTACAATAAGTTTCTGAATG
Cyclin Dl CCND1 Forward ACGAAGGTCTGCGCGTGTT 323
Reverse CCGCTGGCCATGAACTACCT
Cyclin El CCNE1 Forward ATCAGCACTTTCTTGAGCAACA 122
Reverse TTGTGCCAAGTAAAAGGTCTCC
Cell division cycle 25A CDC25A Forward TAAGACCTGTATCTCGTGGCTG 131
Reverse CCCTGGTTCACTGCTATCTCT
Cyclin-dependent kinase 1 CDK1 Forward TCGAAAGCCAAGATAAGCAAC 137
Reverse CCGCAACAGGGAAGAACAGT
Cyclin-dependent kinase 2 CDK2 Forward GCTAGCAGACTTTGGACTAGCCAG 85
Reverse AGCTCGGTACCACAGGGTCA
Cyclin-dependent kinase 4 CDK4 Forward CTGGTGTTTGAGCATGTAGACC 102
Reverse AAACTGGCGCATCAGATCCTT
Cyclin-dependent kinase inhibitor 1A (p21) CDKN1A Forward CCTCATCCCGTGTTCTCCTTT 97
Reverse GTACCACCCAGCGGACAAGT
Cyclin-dependent kinase inhibitor 1B (p27) CDKN1B Forward CTGCAACCGACGATTCTTCTACT 101
Reverse GGGC GTC TGCTCCACAGA
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) CDKN2A Forward CAACGCACCGAATAGTTACGG 96
Reverse AACTTCGTCCTCCAGAGTCGC
Cadherin type 1 CDH1 Forward ACACCCGGGACAACGTTTA 81
Reverse TGTGCAGCTGGCTCAAGTC
Cadherin associated protein, alpha 1 CTNNA1 Forward CCATGCAGGCAACATAAACTTC 81
Reverse GGCTCCAACAGTCTCTCAACT
Cadherin associated protein, beta 1 CTNNB1 Forward C CCACTGGCCTCTGATAAAGG 80
Reverse ACGCAAAGGTGCATGATTTG
Cadherin associated protein, gamma CTNNG Forward AACAAGAACAACCCCAAGTT 134
Reverse TAGTTACGCATGATCTGCAC
E2F transcription factor 1 E2F1 Forward AGATGGTTATGGTGATCAAAGCC 72
Reverse ATCTGAAAGTTCTCCGAAGAGTCC
v-ets erythroblastosis virus E26 oncogene homolog 2 ETS2 Forward CCCCTGTGGCTAACAGTTACA 222
Reverse AGGTAGCTTTTAAGGCTTGACTC
Fibronectin 1 FN1 Forward CCCATCAGCAGGAACACCTT 84
Reverse GGCTCACTGCAAAGACTTTGAA
v-fos FBJ murine osteosarcoma viral oncogene homolog FOS Forward TGCCTCTCCTCAATGACCCTGA 162
Reverse TGCCTCTCCTCAATGACCCTGA
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Forward TGCACCACCAACTGCTTAGC 84
Reverse GGC ATGGACTGTGGTCATGAG
Table W2. (continued )
Genes Abbreviation Primer Sequence (5′-3′) Amplicon Size (bp)
Hypoxanthine phosphoribosyltransferase HPRT Forward TGACACTGGCAAAACAATGCA 94
Reverse GGTCCTTTTCACCAGCAAGCT
HIV-1 Tat interactive protein 2, 30 kDa HTATIP2 Forward CGGAGGGATTTGTTCGTGTTG 104
Reverse AGCTCCTTTAGAGGATAGCAAGT
MET proto-oncogene hepatocyte growth factor receptor) MET Forward TGGTGCAGAGGAGCAATGG 111
Reverse CATTCTGGATGGGTGTTTCCG
Matrix metallopeptidase 1 MMP1 Forward AGCTAGCTCAGGATGACATTGATG 74
Reverse GCCGATGGGCTGGACAG
Matrix metallopeptidase 2 MMP2 Forward CAAAAACAAGAAGACATACATCTT 232
Reverse GCTTCCAAACTTCACGCTC
Matrix metallopeptidase 9 MMP9 Forward TGGGGGGCAACTCGGC 224
Reverse GGAATGATCTAAGCCCAG
Metastasis associated 1 MTA1 Forward GCTGTTACACCACACAGTCTT 166
Reverse GGACTCATGTTACTGCGGTTT
Metastasis associated 2 MTA2 Forward CCGACGGCCTTATGCTCCT 145
Reverse CTGGGCCACCAGATCTTTGAC
v-myc myelocytomatosis viral oncogene homolog (avian) MYC Forward TGCTGCCAAGAGGGTCAAGT 118
Reverse GTGTGTTCGCCTCTTGACATTC
Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (p105) NFκB1 Forward TGCCAACAGATGGCCCATAC 123
Reverse TGTTCTTTTCACTAGAGGCACCA
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha NFκBIA Forward CTCCGAGACTTTCGAGGAAATAC 135
Reverse GCCATTGTAGTTGGTAGCCTTCA
Nonmetastatic cells 1 protein (NM23A) NME1 Forward GCTGCAGCCGGAGTTCAAAC 289
Reverse GCAATGAAGGTACGCTCACAGT
Occludin OCLN Forward TGCCGCGTTGGTGATCTTT 100
Reverse GCCCAGGATAGCACTCACTATT
Plasminogen activator urokinase PLAU Forward CACGCAAGGGGAGATGAA 341
Reverse ACAGCATTTTGGTGGTGACTT
Plasminogen activator urokinase receptor PLA UR Forward AATGGCCGCCAGTGTTACAG 227
Reverse CAGGAGACATCAATGTGGTTC
v-raf-1 murine leukemia viral oncogene homolog 1 RAF Forward TTTCCTGGATCATGTTCCCCT 153
Reverse ACTTTGGTGCTACAGTGCTCA
Retinoblastoma 1 RB1 Forward GAACATCGAATCATGGAATCCCT 116
Reverse AGAGGACAAGCAGATTCAAGGTGAT
SI00 calcium binding protein A4 S100A4 Forward GATGAGCAACTTGGACAGCAA 123
Reverse CTGGGCTGCTTATCTGGGAAG
Serpin peptidase inhibitor, clade B (ovalbumin), member 5 SERPINB5 Forward CTACTTTGTTGGCAAGTGGATGAA 90
Reverse ACTGGTTTGGTGTCTGTCTTGTTG
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1) SERPINE1 Forward CACAAATCAGACGGCAGCACT 85
Reverse CATCGGGCGTGGTGAACTC
Snail homolog 1 SNAIL Forward AATCGGAAGCCTAACTACAGCG 147
Reverse GTCCCAGATGAGCATTGGCA
Synuclein, gamma (breast cancer–specific protein 1) SNCG Forward TGAGCAGCGTCAACACTGTG 64
Reverse GAGGTGACCGCGATGTTCTC
Trefoil factor 1 TFF1 Forward CATCGACGTCCCTCCAGAAGAG 105
Reverse CTCTGGGACTAATCACCGTGCTG
Trefoil factor 3 TFF3 Forward CTTGCTGTCCTCCAGCTCT 124
Reverse CCGGTTGTTGCACTCCTT
Tumor necrosis factor receptor superfamily, member 1A TNFRSF1A Forward TGCCTACCCCAGATTGAGAA 169
Reverse ATTTCCCACAAACAATGGAGTAG
Tumor necrosis factor receptor superfamily member 10B TNFRSF10B Forward AAGACCCTTGTGCTCGTTGT 144
Reverse AGGTGGAC ACAATCCCTCTG
Tumor necrosis factor receptor superfamily member 25 TNFRSF25 Forward ACTGCCAACCATGCCTAGACTG 155
Reverse GAGC CTCCATCCCAGCTTC
Tumor protein p53 (Li-Fraumeni yndrome) TP53 Forward TGCAGCTGTGGGTTGATTCC 396
Reverse AAACACGCACCTCAAAGCTGTTC
Vascular endothelial growth factor-A VEGF-A Forward TACCTCCACCATGCCAAG 148
Reverse GGTACTCCTGGAAGATGTC
Vimentin VIM Forward CCTTGAACGCAAAGTGGAATC 106
Reverse GACATGCTGTTCCTGAATCTGAG
Table W3. qPCR Analysis of Modulation of Gene Expression by Forced Expression of TFF3 in
MCF-7 Cells.
Gene Function Gene Ratio (TFF3/Vec)* P
Cell cycle control and DNA damage repair BRCA1 0.93 7.30e − 01
CDK1 2.41 3.90e − 04
CDC25A 0.79 2.90e − 01
CDC25C 1.13 4.00e − 01
CDK2 0.64 2.20e − 02
CDK4 0.87 5.00e − 03
CDKN1A 0.46 1.90e − 04
CDKN1B 1.01 7.80e − 01
CDKN2A 1.02 8.10e − 01
CCNA1 17.07 1.20e − 04
CCNB1 1.01 5.30e − 01
CCND1 0.61 3.20e − 01
CCNE1 0.74 1.50e − 01
E2F1 0.85 6.00e − 02
RB1 0.94 6.60e − 01
TP53 0.91 1.13e − 01
Adhesion and invasion CTNNA1 0.96 8.60e − 01
CTNNB1 0.99 9.60e − 01
CDH1 0.74 3.00e − 02
CTNNG 0.39 5.00e − 02
FN1 2.43 1.00e − 02
C-MET 1.36 1.40e − 01
MMP1 1.28 4.80e − 01
MMP2 0.98 6.20e − 01
MMP9 1.08 8.40e − 01
MTA1 0.93 3.00e − 01
MTA2 0.98 8.60e − 01
NME1 0.39 1.10e − 06
OCLU 0.80 5.00e − 01
PLAU 1.42 8.80e − 01
PLAUR 0.59 4.00e − 02
SERPINB5 1.25 3.30e − 01
SERPINE1 0.78 5.60e − 01
VEGF 1.35 1.80e − 01
VIMENTIN 2.51 1.80e − 04
SLUG 0.72 1.60e − 01
SNAIL 1.25 1.10e − 01
SNCG 0.27 1.10e − 03
Apoptosis ATM 1.08 5.69e − 01
ARAF 1.21 7.89e − 02
BAD 0.84 4.35e − 01
BAK1 1.01 7.70e − 01
BAX 0.05 4.40e − 04
BCL2 4.52 1.10e − 03
BCL2L1 0.80 1.22e − 01
CASP7 0.41 3.00e − 04
MCL1 1.10 9.00e − 01
S100A4 1.03 7.50e − 01
BIRC5 1.26 1.40e − 01
RAF 0.92 3.00e − 01
HTATIP2 0.44 1.20e − 05
TNFRSF10B 1.14 1.80e − 01
TNFRSF1A 0.81 4.10e − 01
TNFRSF25 1.89 4.00e − 03
Transcription factors ELF5 0.80 6.00e − 01
ETS2 1.12 6.40e − 01
FOS 0.49 1.60e − 02
NFκB1 1.19 2.70e − 01
NFκBIA 2.94 1.59e − 02
*Average of three experiments represents each gene fold changes (P < .05). A positive value indicates
increased gene expression and a negative value indicates decreased gene expression in MCF7-TFF3
cells relative to MCF7-Vec cells.
Figure W3. Production of rabbit polyclonal antibody against TFF3. (A) SDS-PAGE demonstrating formation of the monomeric and dimeric
forms of rhTFF3 protein under nonreducing and reducing conditions, respectively. (B) Affinity binding of TFF3-pAb to rhTFF3 in an ELISA. A
96-well NUNC plate coated with 100 ng of rhTFF3 was incubated with various concentrations of rabbit TFF3-pAb. Bound antibodies were
detected by incubation with goat antirabbit IgG conjugated with horseradish peroxidase and colorimetrically measured at 450 nm. (C) The
detection limit of TFF3-pAb to rhTFF3 in an ELISA. A 96-well NUNC plate coated with various concentrations of rhTFF3 was incubated with
1 μg/ml TFF3-pAb. Bound antibodies were detected by incubation with goat antirabbit IgG conjugated with horseradish peroxidase and
colorimetrically measured at 450 nm. (D) SDS-PAGE Western blot analysis of specificity of TFF3-pAb. Protein samples of purified rhTFF1
and rhTFF3were subjected to SDS-PAGE. The proteinswere transferred to a polyvinylidene fluoridemembrane and probed by either rabbit
TFF1-pAb (top panel) or rabbit TFF3-pAb (bottom panel). (E) MCF-7 and T47D cells were treated with TFF3-pAb at the concentration of
200 μg/ml in 0.5% FBS for 24 hours, and apoptosis was determined by annexin V and PI double staining as described in Materials
and Methods.
Figure W4. Effects of TFF3 polyclonal antibody treatment on morphologic aspects of vital organs of mice. TFF3-pAb was dosed 16 days
after MCF-7 cell implantation and thereafter daily for 2 weeks. Histologic analyses with hematoxylin and eosin staining failed to identify
any histologic alterations in the vital organs including liver, lung, intestine, kidney, and stomach between TFF3-pAb–treated mice and
control IgG–treated mice.
Meta-analysis of Breast Cancer Microarray Data Sets
Data were collected from publicly available breast cancer micro-
array data sets in the cancer microarray database Oncomine (www.
oncomine.org). TFF3 gene expression was log-transformed, median-
centered per array, and SD normalized to one per array. A meta-analysis
approach was used to determine whether higher expression levels of
the gene TFF3 was associated with ER+ or ER− status in breast cancer
patients. Using t values and sample sizes from each study, we calculated
effect sizes by the standardized mean difference method. The within-
study variance for the effect size was calculated as the inverse of the
study sample size. The pooled effect size was estimated in an inter-
cept-only model with the study identifiers as random effects; this model
was weighted by the between-study variance and the estimated within-
study variances that were held constant. The meta-analysis was carried
out using theMIXED procedure in SAS version 9.2 (SAS Institute, Inc,
Cary, NC).
Figure W5. TFF3 expression is correlated with ER-positive status in human mammary carcinoma. Meta-analysis of TFF3 gene expression
profiles of human mammary carcinoma obtained from the Oncomine database showing a positive association of TFF3 mRNA expres-
sion with ER-positive status in mammary carcinoma.
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